NCT04895748 2026-03-03
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Phase 1 Terminated
Clinical Trials
8 trialsNCT04924075 2026-02-24
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07405164 2026-02-12
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Not yet recruiting
NCT03401788 2024-12-03
MK-6482-004
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Active not recruiting
NCT03108066 2024-09-24
MK-3795-003
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Completed
NCT06553339 2024-08-14
A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05843305 2023-05-06
A Study of BPI-452080 in Subjects With Solid Tumors
Betta Pharmaceuticals Co., Ltd.
Phase 1 Unknown
NCT00052013 2017-03-06
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
Novartis
Phase 2 Completed